Autolus Therapeutics plc(6A3A)

Description: Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

---

Keywords: Biotechnology Cancer Biopharmaceutical Treatment Of Cancer Autoimmune Disease Antineoplastic Drugs Multiple Myeloma Neuroblastoma Peripheral T Cell Lymphoma Precision Biosciences Treatment Of Peripheral T Cell Lymphoma Gd2 Glycolipids Investigational Therapy

---

Home Page: www.autolus.com

The Mediaworks
London, W12 7FP
United Kingdom
Phone: 44 20 3829 6230

---

Officers

Exchange: F

Country: DE : Germany

Currency: Euro (€)